Arcadia Biosciences (NASDAQ:RKDA) Announces Quarterly Earnings Results

Posted by Doug Wharley on Nov 8th, 2025

Arcadia Biosciences (NASDAQ:RKDA – Get Free Report) issued its earnings results on Friday. The basic materials company reported $0.62 EPS for the quarter, beating the consensus estimate of ($0.54) by $1.16, FiscalAI reports. Arcadia Biosciences had a negative net margin of 139.36% and a negative return on equity of 34.75%. The company had revenue of $1.30 million during the quarter, compared to analysts’ expectations of $1.90 million.

Arcadia Biosciences Stock Down 5.4%

Arcadia Biosciences stock opened at $3.69 on Friday. The stock has a market cap of $5.04 million, a PE ratio of 3.51 and a beta of 0.57. Arcadia Biosciences has a 12-month low of $2.53 and a 12-month high of $10.31. The business’s 50-day moving average price is $3.72 and its two-hundred day moving average price is $4.12.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Arcadia Biosciences in a research report on Wednesday. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Sell”.

Read Our Latest Analysis on Arcadia Biosciences

Arcadia Biosciences Company Profile

(Get Free Report)

Arcadia Biosciences, Inc produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring.